Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News

About the Cover

Cover image

Cover image expansion

Anti-VEGF therapy appears to benefit patients with glioblastoma in part via its anti-edema mechanisms. The extent to which such edema reduction may benefit patients is not clear, either in terms of survival or neurological function. In a study of 30 patients treated with cediranib, imaging changes after one day of treatment correlated with progression-free and overall survival, and a “vascular normalization index” that combines imaging and blood biomarkers was highly correlated with these long-term outcomes. Imaging can assess a variety of mechanisms of anti-VEGF therapies, and one such imaging method is diffusion tensor imaging, a method particularly suited for visualizing white matter tracts and the edema which may surround and possibly impair them. The cover image shows diffusion tractography before (top) and four months after treatment with cediranib (bottom), with re-emergence of the white matter tracts clearly evident. The reduction in edema allows markedly improved visualization of frontal lobe white matter tracts; the direct functional significance of these changes remains to be elucidated, but cediranib and other anti-VEGF therapies have been reported to show increased overall survival in single-arm studies. Further mechanistic imaging and randomized trials are underway to better understand the potential benefit of these agents, as well as validate the predictive performance of the vascular normalization index. A movie of these data is available online through a Supplementary Data link from this article (doi: 10.1158/0008-5472.CAN-09-0814). For details, see the article by Sorensen and colleagues on page 5296 of this issue.

Back to top
PreviousNext
Cancer Research: 69 (13)
July 2009
Volume 69, Issue 13
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author

Sign up for alerts

Issue Highlights

  • A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
  • Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
  • Murine Gammaherpesvirus 68 Infection of IFNγ Unresponsive Mice: A Small Animal Model for Gammaherpesvirus-Associated B-Cell Lymphoproliferative Disease
Advertisement
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement